Disease activity, patient-reported outcomes, and medications used during 12-month followup.
| No. Patients | Patients with RA, 3 Months | Patients with UA, 3 Months | p | Patients with RA, 12 Months | Patients with UA, 12 Months | p | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 310 | %* | 96 | %* | 310 | %* | 96 | %* | |||
| DAS28, mean (SD) | 2.3 (1.1) | 76 | 2.4 (1.0) | 68 | 0.39 | 2.1 (1.0) | 80 | 1.9 (0.9) | 80 | 0.13 |
| DAS28(3), mean (SD) | 2.2 (1.1) | 87 | 2.3 (0.9) | 79 | 0.65 | 2.1 (0.9) | 91 | 1.8 (0.9) | 84 | 0.12 |
| PtGA (0–100), median (IQR) | 25 (5–46) | 79 | 18 (5–37) | 69 | 0.34 | 23 (6–47) | 80 | 21 (9–39) | 84 | 0.81 |
| PGA (0–100), median (IQR) | 5 (0–20) | 53 | 10 (0.5–20) | 39 | 0.20 | 5 (0–15) | 65 | 5 (0–15) | 59 | 0.75 |
| SJC28, mean (SD) | 0.9 (2.1) | 89 | 0.6 (1.4) | 80 | 0.75 | 0.5 (1.4) | 91 | 0.5 (1.2) | 88 | 0.57 |
| TJC28, mean (SD) | 1.1 (2.6) | 89 | 1.1 (2.1) | 80 | 0.20 | 0.7 (1.8) | 91 | 0.7 (1.6) | 88 | 0.76 |
| SJC46, mean (SD) | 1.7 (3.3) | 89 | 1.1 (2.0) | 80 | 0.54 | 0.9 (2.2) | 90 | 0.6 (1.6) | 88 | 0.16 |
| TJC46, mean (SD) | 2.3 (4.6) | 88 | 2.1 (3.7) | 80 | 0.38 | 1.5 (3.3) | 90 | 1.1 (2.3) | 88 | 0.75 |
| CRP, mg/l, mean (SD) | 6 (16) | 90 | 5 (8) | 80 | 0.40 | 6 (17) | 91 | 6 (17) | 85 | 0.76 |
| ESR, mm/h, mean (SD) | 13 (13) | 89 | 12 (13) | 80 | 0.60 | 11 (12) | 91 | 9 (10) | 84 | 0.016 |
| Pain (0–100), mean (SD) | 24 (23) | 79 | 25 (23) | 69 | 0.57 | 23 (22) | 80 | 25 (23) | 83 | 0.56 |
| HAQ (0–3), median (IQR) | 0.4 (0–0.9) | 76 | 0.4 (0–0.8) | 67 | 0.63 | 0.4 (0–0.9) | 79 | 0.4 (0–0.8) | 82 | 0.41 |
| DAS28 remission, % | 63.8 | 76 | 56.9 | 68 | 0.31 | 69 | 80 | 72.7 | 80 | 0.53 |
| DAS28(3 variables) remission, % | 67.2 | 87 | 57.9 | 80 | 0.13 | 71.2 | 91 | 79.0 | 84 | 0.16 |
| Boolean remission, % | 27.1 | 83 | 25.0 | 71 | 0.72 | 28.1 | 84 | 26.3 | 83 | 0.75 |
| Boolean(3 variables) remission, % | 28.6 | 82 | 26.5 | 71 | 0.73 | 30.3 | 82 | 29.6 | 84 | 0.91 |
| Medications | 100 | 100 | 97 | 98 | ||||||
| Triple therapy, % | 20 | 6.3 | 0.002 | 19 | 5.3 | 0.001 | ||||
| Combination of MTX + HCQ/SSZ, % | 33 | 28 | 0.41 | 36 | 36 | 0.90 | ||||
| MTX mono, % | 36 | 43 | 0.25 | 30 | 29 | 0.75 | ||||
| Other mono, % | 8.4 | 17 | 0.02 | 8.4 | 12 | 0.33 | ||||
| Other combo, % | 0.3 | 3.1 | 0.015 | 2.7 | 7.4 | 0.035 | ||||
| No csDMARD, % | 2.6 | 3.1 | 0.77 | 3.7 | 11 | 0.009 | ||||
| Prednisolone,% | 83 | 78 | 0.29 | 66 | 61 | 0.39 | ||||
| bDMARD, % | 0 | 0 | 2.7 | 1.1 | 0.36 | |||||
↵* Percentages refer to the percentage of patients with data available. RA: rheumatoid arthritis; UA: undifferentiated arthritis; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic DMARD; IQR: interquartile range; HAQ: Health Assessment Questionnaire; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PtGA: patient’s global assessment; PGA: physician’s global assessment; TJC28: 28-joint tender joint count; SJC28: 28-joint swollen joint count; TJC46: 46-joint TJC; SJC46: 46-joint SJC; MTX: methotrexate; SSZ: sulfasalazine; HCQ: hydroxychloroquine.